GB-115

• 1 g powder (neat research material)​
• Dry-fill capsules (2.5 mg per capsule; 60-count; 150 mg total)​
• Liquid solution (5 mg/mL in PEG-400; 30 mL total volume; 150 mg total)​

• CCK pathway modulation: GB-115 is described in the research literature as a cholecystokinin receptor antagonist, a pathway that has been linked with anxiety like signaling in multiple models.
• Anxiolytic signaling without tolerance patterns: In rodent work, GB-115 maintained anxiolytic effects across repeated dosing, contrasting with patterns often seen with benzodiazepines.
• Immunomodulatory effects in preclinical models: Separate animal data reports “immunocorrecting” activity and stimulation of some immune parameters in specific mouse models.

GB‑115 is commonly investigated in research for

• Anxiety reduction: In a small clinical sample reported in a European Psychiatry abstract, median Hamilton Anxiety (HAM A) scores fell from 22 to 5 over 21 days, which is about a 77% reduction from baseline.
• Fatigue improvement: In that same report, fatigue severity scores also decreased over the same period.
• Less “withdrawal style” concern vs classic sedatives (preclinical): Rodent data specifically evaluated tolerance/withdrawal type effects and reported no tolerance or withdrawal syndrome signals under the conditions tested.

GB-115 is often described as well tolerated in research settings but the public human data that’s easily accessible is limited.

• Preclinical work reports no tolerance development and no withdrawal syndrome in the model tested.
• Human safety details (rates of side effects, labs, discontinuations) are not richly reported in the abstract level source, so safety confidence is still constrained.

• Utilized conceptually alongside other CCK receptor ligands, neuromodulators, and anxiolytic candidates in comparative pharmacology studies.​
• Positioned as a tool compound for dissecting CCK receptor–mediated anxiety and cognition pathways rather than as part of combination “therapies” or consumer stacks.​
• No consumer-level interaction data or clinical drug–interaction profiles are documented, as it is not intended for therapeutic use.​